These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2952999)

  • 21. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598
    [No Abstract]   [Full Text] [Related]  

  • 22. Thrombolysis in coronary occlusion--the full circle.
    Bauer GE
    Aust N Z J Med; 1989 Apr; 19(2):85-7. PubMed ID: 2504138
    [No Abstract]   [Full Text] [Related]  

  • 23. Coronary thrombolysis: practical considerations.
    Eisenberg PR; Jaffe AS
    Cardiol Clin; 1987 Feb; 5(1):129-41. PubMed ID: 3103918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Thrombolytic therapy of acute heart infarct].
    Arnold AE; Simoons ML; Lubsen J
    Ned Tijdschr Geneeskd; 1989 Feb; 133(7):335-8. PubMed ID: 2494462
    [No Abstract]   [Full Text] [Related]  

  • 25. Thrombolytic treatment in acute myocardial infarction.
    Acar J; Vahanian A; Michel PL; Slama M; Cormier B; Roger V
    Semin Thromb Hemost; 1987 Apr; 13(2):186-200. PubMed ID: 2957791
    [No Abstract]   [Full Text] [Related]  

  • 26. [Coronary reperfusion by anistreplase (Eminase) used intravenously during the acute phase of myocardial infarction].
    Monassier JP; Hanssen M; Fritz A; Katz O; Hertzog M
    Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():21-4. PubMed ID: 2108642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombolytic therapy for myocardial infarction.
    McNeill AJ; Adgey AA
    Lancet; 1988 Apr; 1(8591):938-9. PubMed ID: 2895857
    [No Abstract]   [Full Text] [Related]  

  • 28. Acylated streptokinase--plasminogen complex in patients with acute myocardial infarction.
    Walker ID; Davidson JF; Rae AP; Hutton I; Lawrie TD
    Thromb Haemost; 1984 Apr; 51(2):204-6. PubMed ID: 6377564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Socioeconomic implications of the practice of thrombolysis in the acute stage of myocardial infarction].
    Herve C; Castiel D; Gaillard M; Daussac C; Leroux V; Jan F; Castaigne A
    Arch Mal Coeur Vaiss; 1989 Mar; 82(3):353-8. PubMed ID: 2502091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The APSAC interventional mortality study (AIMS) trial: mortality data.
    Julian DG
    Clin Cardiol; 1990 Mar; Suppl 5():V20-1; discussion V27-32. PubMed ID: 2182236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study of survival using anistreplase (Eminase)].
    Murray RG
    Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():37-40. PubMed ID: 2108645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eligibility for thrombolytic therapy in acute myocardial infarction.
    Jagger JD; Murray RG; Davies MK; Littler WA; Flint EJ
    Lancet; 1987 Jan; 1(8523):34-5. PubMed ID: 2879104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction.
    Hoffmann JJ; Van Rey FJ; Bonnier JJ
    Thromb Res; 1985 Mar; 37(5):567-72. PubMed ID: 3920779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pre-hospital thrombolysis].
    Castaigne A; Hervé C; Duval-Moulin AM; Dubois-Randé JL; Merlet P; Hittinger L
    Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():41-5. PubMed ID: 2108646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients with acute myocardial infarction.
    Kasper W; Erbel R; Meinertz T; Drexler M; Rückel A; Pop T; Prellwitz W; Meyer J
    J Am Coll Cardiol; 1984 Aug; 4(2):357-63. PubMed ID: 6429226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Coronary thrombolysis in acute myocardial infarction. Initial experience with an intravenous thrombolytic agent].
    Martínez Ríos MA; Cárdenas M; Gil M; Iturbe I; Alarcón A; Soní J
    Arch Inst Cardiol Mex; 1984; 54(1):3-9. PubMed ID: 6372717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should we intervene following thrombolytic therapy? The SWIFT study in progress. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():229-30. PubMed ID: 3315599
    [No Abstract]   [Full Text] [Related]  

  • 38. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antistreplase introduced for therapy of acute myocardial infarction.
    Clin Pharm; 1990 Feb; 9(2):78-9. PubMed ID: 2407423
    [No Abstract]   [Full Text] [Related]  

  • 40. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.